HR-positive

FDA Approves Truqap Plus Faslodex for Advanced HR-Positive Breast Cancer
Pharm Exec
Fri, 11/17/23 - 10:09 am
AstraZeneca
Truqap
breast cancer
HR-positive
ASCO: Pfizer's Ibrance fails to extend lives in newly diagnosed breast cancer. Will doctors switch gears to Novartis, Lilly?
Fierce Pharma
Sun, 06/5/22 - 11:40 pm
ASCO 2022
Pfizer
Ibrance
HR-positive
HER2-negative breast cancer
breast cancer
clinical trials
ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?
Fierce Pharma
Mon, 06/4/18 - 09:31 am
Novartis
Kisqali
metastatic breast cancer
ASCO 2018
HR-positive
HER2-negative breast cancer